UNSPSC 51391604: Isometheptene

This classification denotes an adrenergic agent with the molecular formula C9H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7L24THH6T, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but generally known as isometheptene, which bears US NIH Compound Identifier 22297. European Medicines Agency schedules Isometheptene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08324MIG.

UNSPSC 51391604 Isometheptene, a Commodity code, represents pharmaceutical products and drug-related supplies that state and local governments procure to support public health, emergency response, and community wellness programs. Recent state and local solicitations under this code show demand for naloxone (opioid-overdose reversal medication) and related pharmaceutical supplies, typically through county health departments and state health and human services commissions. The work involves procurement of finished pharmaceutical products for distribution through community health facilities, with vendors responsible for meeting quality, compliance, and delivery requirements including drug-free workplace certification, E-Verify compliance, and insurance coverage mandates. Issuing bodies include county health departments and state-level health commissions pursuing these purchases to address public health priorities such as opioid crisis response and pharmacy benefit program modernization.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and pharmaceutical fulfillment strategies outside traditional pharmacy benefit manager arrangements. The Texas RFI functions as market research preceding a formal RFP and does not include a binding award timeline or budget commitment at this stage.